HC Wainwright Has Optimistic Outlook of NMRA Q2 Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at HC Wainwright boosted their Q2 2025 EPS estimates for shares of Neumora Therapeutics in a note issued to investors on Tuesday, March 4th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.42) per share for the quarter, up from their previous estimate of ($0.43). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Neumora Therapeutics’ Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.43) EPS, FY2025 earnings at ($1.74) EPS, FY2026 earnings at ($1.68) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($1.51) EPS and FY2029 earnings at ($0.20) EPS.

A number of other analysts have also commented on the company. William Blair reissued an “outperform” rating on shares of Neumora Therapeutics in a research note on Wednesday, January 15th. Bank of America cut their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Needham & Company LLC restated a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $4.00 price target on shares of Neumora Therapeutics in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.50.

Neumora Therapeutics Stock Up 6.3 %

Shares of NMRA stock opened at $1.52 on Thursday. Neumora Therapeutics has a twelve month low of $1.35 and a twelve month high of $21.00. The stock’s fifty day simple moving average is $2.63 and its 200 day simple moving average is $8.71. The firm has a market capitalization of $245.57 million, a P/E ratio of -0.81 and a beta of 2.59.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in Neumora Therapeutics during the fourth quarter worth $61,000. PNC Financial Services Group Inc. acquired a new stake in Neumora Therapeutics during the 4th quarter worth about $64,000. Quantbot Technologies LP bought a new position in shares of Neumora Therapeutics in the 4th quarter worth about $92,000. PEAK6 LLC bought a new position in shares of Neumora Therapeutics in the 4th quarter worth about $117,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at about $135,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.